Clinic Roundup

May 2012
BioWorld Today;5/23/2012, p5
This section offers news briefs on clinical trials. A Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron to treat peritumoral brain edema associated with cerebral tumors has been completed by Celtic Pharmaceutical Holdings LP. Enrollment in the Phase II study of Diamyd Medical AB of Sweden to test NP2 Enkephalin in cancer pain has been completed.


Related Articles

  • Diamyd Completes Recruitment In Gene Therapy Pain Trial. Sheridan, Cormac // BioWorld International;5/23/2012, p2 

    The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after...

  • Diamyd Eyes Spring Start for Phase III Diabetes Trial. Sheridan, Cormac // BioWorld International;2/20/2008, Vol. 13 Issue 8, p2 

    The article reports on the plan by Stockholm, Sweden-based Diamyd Medical AB to begin a Phase III clinical trial of its therapeutic vaccine for Type I diabetes in spring. The U.S. Food and Drug Administration (FDA) questioned a minor aspect of the vaccine's manufacturing process. According to...

  • ADA 2011.  // BioWorld Today;6/29/2011, Vol. 22 Issue 125, p9 

    The article focuses on results presented by Diamyd Medical AB at the 2011 American Diabetes Association meeting from a European trial of its diabetes immunotherapy Diamyd.

  • CLINIC ROUNDUP.  // BioWorld Today;5/1/2007, Vol. 18 Issue 84, p5 

    The article presents updates on the biotechnology industry. Aastrom Biosciences Inc. has initiated its U.S. Phase IIb multicenter clinical trial to treat peripheral arterial disease (PAD) patients. Advaxis Inc. has competed recruiting patients in its Phase I/II trial of Lovaxin C, a...

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2007, Vol. 18 Issue 211, p4 

    This section offers news briefs on clinical trials of drugs as of October 30, 2007. Addex Pharmaceuticals has presented data on a Phase IIa trial of ADX10059 to treat gastroesophageal reflux disease (GERD). BioLineRx Ltd. has presented results on its Phase II trial of the GABA enhanced...

  • Clinic Roundup.  // BioWorld Today;10/4/2011, Vol. 22 Issue 192, p4 

    This section offers news briefs related to clinical trials. Alkermes PLC of Ireland started a Phase IIb study of an oral, peripherally restricted opioid antagonist in development for opioid-induced constipation (OIC). Celtic Pharmaceutical Holdings LP of New York completed enrollment in a...

  • Clinic Roundup.  // BioWorld Today;6/28/2012, Vol. 23 Issue 125, p8 

    This section offers news briefs pertaining to clinical trials worldwide, as of June 2012. New Jersey-based Amicus Therapeutics Inc. has reported preliminary data from a Phase II drug-drug interaction showing no drug-related adverse events for pharmacological chaperone AT2220 co-administered with...

  • Celtic Pharma Announces Successful Completion of Phase I/II study of Xerecept(r) in Pediatric Patients with Cerebral Tumors.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article reports on an announcement made by Celtic Pharmaceutical Holdings L.P related to the completion of Phase I/II study of an investigational new drug Xerecept in the pediatric patients who are dependent on the steroid. It informs that the drug is used for the treatment of peritumoral...

  • CLINIC ROUNDUP.  // BioWorld Today;5/3/2010, Vol. 21 Issue 84, p8 

    This section presents an update on clinical research related to biotechnology. Abraxis BioScience Inc. demonstrated the antitumor activity of Abraxane combined with carboplatin in patients with advanced non-small-cell lung cancer. BioCancell Therapeutics Inc. concluded its Phase IIb trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics